# Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease

> **NCT00602680** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 1 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** SSR180711C
- **DRUG:** donepezil
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00602680
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Insufficient expected benefit risk
- **Last updated:** 2009-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00602680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00602680, "Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00602680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*